Amgen announces Phase 3 data on Nplate®

Today, Amgen announced data from the Phase 3 study to test the safety and efficacy of Nplate® in patients with immune thrombocytopenia, a bleeding disorder caused by a reduced platelet supply in the blood. The results show that the drug induced a rapid platelet response in patients with low platelet counts or bleeding symptoms, all while staying consistently safe. In the 407 patients enrolled in the study, approximately 90 percent achieved all the platelet response definitions, and around 91 percent experienced a doubled platelet count. The drug was administered once a week over 44 weeks with dosage adjusted according to platelet count. Some common adverse events were headache, arthralgia and fatigue.

SOURCE: Amgen Press Release